1Ansell J,Hirsh J,Poller L,et al.The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy[].Chest.2004
2Rieder MJ,Rieder AP,Gage BF,et al.Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose[].New England Journal of Medicine The.2005
3AS Go,EM Hylek,Y Chang.Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice?[].The Journal of The American Medical Association.2003
4Staton,C.A.,Lewis,C.E.Angiogenesis inhibitors found within the haemostasis pathway[].Journal of Cellular and Molecular Medicine.2005
5Hirsh,J,Fuster,V,Ansell,J,Halperin,JL.American heart association/american college of cardiology foundation guide to warfarin therapy[].Circulation.2003
6Ma MK,Woo MH,McLeod HL.Genetic basis of drug metabolism[].American Journal of Health System Pharmacy.2002
9Zhang JE,Jorgensen AL,Alfirevic A,et al.Effects of CYP4F2 genetic polymorphisms and haplotypes on clinical outcomes in patients initiated on warfarin therapy[J].Pharmacogenet Genomics,2009,19(10):781-789.
10Yael Lurie,Ronen Loebstein,Daniel Kumik,et al.Warfarin and vitamin K intake in the era of pharmacogenetics[J].Br J Clin Pharmacol,2010,70(2):164-170.
